文章：

急性髓系白血病：当前进展与未来方向

Acute myeloid leukemia: current progress and future directions

原文发布日期：2021-02-22

DOI: 10.1038/s41408-021-00425-3

类型: Review Article

开放获取: 是

英文摘要：

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.
 

摘要翻译： 

对急性髓系白血病（AML）生物学机制及治疗方法的认识正快速进展。自2017年以来，已有九种药物获批用于AML的不同适应症，其中包括维奈托克、FLT3抑制剂、IDH抑制剂等多种靶向疗法。AML的治疗管理十分复杂，需要专业知识以实现最佳治疗方案并取得最优疗效。AML存在多种亚型，各自需要差异显著的治疗策略。本篇综述中，我们总结了驱动AML的重要病理生理机制，回顾了当前标准临床实践中的治疗方法，并探讨了当下与未来的研究方向。

原文链接：

Acute myeloid leukemia: current progress and future directions